 We have some audience questions, or at least I think we have time for one that were sent in early. So Lisa, if you could read us the question. We have one from Christine Lee from Friends of Cancer Research. Is finding balance between innovation, progression, and affordable drugs possible? If so, what does it require, and what can Congress do to actively support this balance? That's just such a simple question. I don't know how to answer it. As we've talked during the talk, I'll just say this. It's a delicate balance. I mean, it's a...